CSL Loses Bull on Concerns Over Plasma Business, Vaccine Spin-Off -- Market Talk

Dow Jones

Aug 20

2353 GMT - Bell Potter analyst Thomas Wakim downgrades Australia-listed pharmaceuticals company CSL to hold from buy after the company reported annual results and announced a spin-off of its vaccine unit Seqirus. Wakim says guidance for earnings growth was below consensus and that the 2H performance of CSL's Behring unit, which includes CSL's marquee plasma business, was underwhelming. Wakim also says the Seqirus spin-off seems unlikely to drive a near-term valuation uplift given falling vaccination rates and a soft growth outlook. He adds that there's now uncertainty regarding the forecasts of the de-merged company. CSL's shares tumbled nearly 17% yesterday after the result. (mike.cherney@wsj.com)

(END) Dow Jones Newswires

August 19, 2025 19:53 ET (23:53 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2560457611"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560457611\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560457611?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 07:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560457611","market":"us","top_or_hot":-1,"title":"CSL Loses Bull on Concerns Over Plasma Business, Vaccine Spin-Off -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2353 GMT - Bell Potter analyst Thomas Wakim downgrades Australia-listed pharmaceuticals company CSL to hold from buy after the company reported annual results and announced a spin-off of its vaccine unit Seqirus. Wakim says guidance for earnings growth was below consensus and that the 2H performance of CSL's Behring unit, which includes CSL's marquee plasma business, was underwhelming. Wakim also says the Seqirus spin-off seems unlikely to drive a near-term valuation uplift given falling vaccination rates and a soft growth outlook. He adds that there's now uncertainty regarding the forecasts of the de-merged company. CSL's shares tumbled nearly 17% yesterday after the result. (mike.cherney@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 19, 2025 19:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Loses Bull on Concerns Over Plasma Business, Vaccine Spin-Off -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Loses Bull on Concerns Over Plasma Business, Vaccine Spin-Off -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-20 07:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2353 GMT - Bell Potter analyst Thomas Wakim downgrades Australia-listed pharmaceuticals company CSL to hold from buy after the company reported annual results and announced a spin-off of its vaccine unit Seqirus. Wakim says guidance for earnings growth was below consensus and that the 2H performance of CSL's Behring unit, which includes CSL's marquee plasma business, was underwhelming. Wakim also says the Seqirus spin-off seems unlikely to drive a near-term valuation uplift given falling vaccination rates and a soft growth outlook. He adds that there's now uncertainty regarding the forecasts of the de-merged company. CSL's shares tumbled nearly 17% yesterday after the result. (mike.cherney@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 19, 2025 19:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7511","symbol_name":"ESG概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2560457611","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560457611","pubTimestamp":1755647580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2353 GMT - Bell Potter analyst Thomas Wakim downgrades Australia-listed pharmaceuticals company CSL to hold from buy after the company reported annual results and announced a spin-off of its vaccine unit Seqirus. Wakim says guidance for earnings growth was below consensus and that the 2H performance of CSL's Behring unit, which includes CSL's marquee plasma business, was underwhelming. Wakim also says the Seqirus spin-off seems unlikely to drive a near-term valuation uplift given falling vaccination rates and a soft growth outlook. He adds that there's now uncertainty regarding the forecasts of the de-merged company. CSL's shares tumbled nearly 17% yesterday after the result. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7511":"ESG概念","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7508":"医药生物股","BK7501":"新冠治疗股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","CSL.AU":"CSL LIMITED","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","CSL":"卡莱尔伙伴","BK4086":"建筑产品","BK7067":"生物科技"},"translate_title":"CSL因对血浆业务、疫苗分拆的担忧而失去牛市——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9,"CSL":1},"content_text":"2353 GMT - Bell Potter analyst Thomas Wakim downgrades Australia-listed pharmaceuticals company CSL to hold from buy after the company reported annual results and announced a spin-off of its vaccine unit Seqirus. Wakim says guidance for earnings growth was below consensus and that the 2H performance of CSL's Behring unit, which includes CSL's marquee plasma business, was underwhelming. Wakim also says the Seqirus spin-off seems unlikely to drive a near-term valuation uplift given falling vaccination rates and a soft growth outlook. He adds that there's now uncertainty regarding the forecasts of the de-merged company. CSL's shares tumbled nearly 17% yesterday after the result. (mike.cherney@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 19, 2025 19:53 ET (23:53 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}